Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy for locally advanced transitional cell carcinoma of the bladder in patients not suitable for cisplatin-based chemotherapy - a phase 3 study

Trial Profile

Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy for locally advanced transitional cell carcinoma of the bladder in patients not suitable for cisplatin-based chemotherapy - a phase 3 study

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
    • 16 Feb 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
    • 16 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top